

EVERYLIFE
FOUNDATION
FOR RARE DISEASES



2025 ANNUAL REPORT

everylifefoundation.org

THE EVERYLIFE FOUNDATION TEAM

Executive Leadership Team

- Michael Pearlmutter, Chief Executive Officer
- Annie Kennedy, Chief Mission Officer
- Will Nolan, Chief Marketing & Communications Officer
- Trova O’Heffernan, Chief Operating Officer

Policy, Advocacy, & Patient Engagement

- Amy Aikins, Director of Rare Access Program
- Lindsey Cundiff, Associate Director of Policy Programs
- Syed Ejaz, State Advocacy Manager
- Abbey Hauser, Associate Director of Community Engagement
- Kendly Jones, RDLA Program Manager
- Mary Michael Kelley, Vice President, Patient Community Engagement
- Baillie McGowan, Director of Policy Research
- Kathryn Poe, State Policy Manager
- Stephanie Riordan, Senior Director of Patient Programs
- Laura Romano, YARR Program Manager
- Dylan Simon, Senior Director of Policy
- Jamie Sullivan, Senior Vice President of Policy and Advocacy
- Shannon von Felden, Vice President of Advocacy



Operations

- Lina Arslanian, Associate Director of Finance
- Leigh Bethea, Director of Events
- Charey Jackson, Executive Administrator
- Alyssa Terwall, Vice President of Operations & Events

Development

- Carrie Borrello, Annual Giving Manager
- Ted Brasfield, Vice President of Alliance Development
- Stephanie Siddiqi, Director of Development
- Collin Sovie, Alliance Development Manager
- James Uyeda, Vice President of Individual Giving

Marketing & Communications

- Brenda Colmenares, Director of Communications
- Katie Wagman, Policy Communications Manager



Our Mission

The EveryLife Foundation for Rare Diseases is a 501(c)(3) nonprofit, nonpartisan organization powered by the rare disease community to improve health outcomes by driving change through evidence-based policy, leading science-driven policy and regulatory research, activating the community to advocate for their rights and needs, and strengthening the rare disease community.

TABLE OF CONTENTS

3	Letter from the CEO
4	Shaping Rare Disease Policy
5-6	The Year in Policy
7-8	Emboldening the Patient Community: A Year of Advocacy
9-10	Financial Support to the Community
11	Financials
12	Board of Directors



LETTER FROM THE CEO

Dear Friends and Supporters,

As I reflect on 2025, I am filled with gratitude and optimism for what we have accomplished together on behalf of the rare disease community. Every achievement highlighted in this report is a testament to the power of patients, caregivers, advocates, researchers, industry partners, policymakers, and supporters working toward a shared vision: a world where every person affected by a rare disease will thrive.

This year, we strengthened our role as a leading voice for rare disease policy and advocacy. We expanded our Community Congress to 387 member organizations, advanced critical policy research initiatives, mobilized more than 800 advocates during Rare Disease Week on Capitol Hill, and continued driving progress on priorities including newborn screening modernization, the Rare Pediatric Priority Review Voucher Program, and access to innovative therapies.

Our advocacy community continued to grow and inspire. Through Rare Across America, state advocacy days, youth engagement programs, and the Young Adult Rare Representatives network, thousands of advocates connected, made their voices heard, and helped educate policymakers about the urgent needs of the rare disease community.

We also deepened our direct support for patients and families. From awarding 108 scholarships and expanding mentorship opportunities for scholarship recipients to providing grants, travel assistance, and educational resources, we remained committed to reducing barriers and creating opportunities for connection, empowerment, and success.

None of this would be possible without your partnership. Together, we are building momentum, advancing solutions, and creating meaningful change for millions of individuals and families affected by rare diseases.

Thank you for standing with us and helping make every life count.

With deep appreciation,

Michael Pearlmutter
Chief Executive Officer
The EveryLife Foundation for Rare Diseases

SHAPING RARE DISEASE POLICY

COMMUNITY CONGRESS

Since 2015, the EveryLife Foundation's Community Congress has brought together patient organizations, industry leaders, and other rare disease stakeholders to provide support and insight on urgent policy issues and our programs and initiatives.

Thank You to Our 2025 Working Group Co-Chairs

Access & Value



Parisa Sanandaji
Stoke Therapeutics




Brigid Brennan,
Friedreich's Ataxia
Research Alliance

Newborn Screening & Diagnostics



Matthew Ellinwood
National MPS Society



Andrew Herbert
Takeda

Public Policy Regulatory



Lauren Stanford
Parent Project
Muscular Dystrophy



Gina Cioffi Loud
Chiesi Group

Regulatory



Kim Hollander
Oxalosis & Hyperoxaluria
Foundation




Jewell Martin
BioMarin
Pharmaceutical



Thank you to the Rare Disease Congressional Caucus Co-Chairs

Representative Gus Bilirakis (FL), **Representative** Doris Matsui (CA), **Senator** Amy Klobuchar (MN), and **Senator** Roger Wicker (MS)



THE YEAR IN POLICY



Policy Research Drives Our Mission

Throughout 2025, the EveryLife Foundation advanced a robust policy research agenda to better understand the needs of the rare disease community and inform evidence-based advocacy.

Key Initiatives Included:

- **Tufts University/NEWDIGS Collaboration:** Developed 10-year projections on the pediatric rare disease therapy pipeline, treatment access, and market trends.
- **International Economic Burden Study:** Partnered with stakeholders across Europe to assess the economic impact of rare diseases on patients, caregivers, and healthcare systems.
- **Medicaid Utilization Analysis:** Conducted a comprehensive assessment of Medicaid's role in supporting the rare disease community.
- **Newborn Screening Roadmap:** Continued efforts to identify opportunities to strengthen and modernize the newborn screening system.
- **Rare Access Initiative:** Advanced patient engagement in payer decision-making through educational resources, committee opportunities, and community-driven recommendations.

Legislative & Administrative Engagement

The EveryLife Foundation remained a leading voice for the rare disease community throughout a year of significant policy activity.

Highlights Included:

- Coordinated a community petition with more than 10,000 signatures supporting federal leadership, biomedical research funding, and public health infrastructure.
- Engaged Congress and federal agencies on the Rare Pediatric Priority Review Voucher (PRV) Program, Newborn Screening Saves Lives Reauthorization Act (NBSSLA), Accelerating Kids' Access to Care Act (AKACA), and Medicaid policy.
- Developed coalition language and conducted congressional outreach to support newborn screening modernization efforts.
- Submitted letters, comments, and recommendations to congressional committees and federal agencies on issues impacting rare disease patients and families.

Regulatory Agency Engagement

The EveryLife Foundation continued meaningful engagement with federal agencies and regulatory partners to ensure patient perspectives informed policy development.

Key Areas of Focus Included:

- Supporting implementation and strategic development of the Rare Disease Innovation Hub (RDIH).
- Engaging FDA on patient engagement, regulatory modernization, and rare disease drug development policies.
- Monitoring progress of the NCATS Whole Genome Sequencing Pilot, CMS Cell and Gene Therapy Access Model, and ARPA-H rare disease initiatives.
- Supporting efforts to strengthen the newborn screening ecosystem through education, collaboration, and stakeholder engagement.

Appropriators' Support for Rare Disease Priorities

The EveryLife Foundation worked with congressional offices and community partners to support sustained federal investment in rare disease programs and infrastructure.

Advocacy Efforts Helped Reinforce Support for:

- The Rare Disease Innovation Hub and its strategic agenda.
- Rare disease research at NCATS.
- Federal newborn screening programs.
- Biomedical and public health research funding critical to rare disease patients and families.


Rare Pediatric Priority Review Voucher Advocacy

The EveryLife Foundation continued its leadership role in advancing reauthorization of the Rare Pediatric Priority Review Voucher Program.

Throughout the Year, the Foundation:

- Coordinated community sign-on efforts and stakeholder engagement.
- Supported congressional outreach and committee engagement.
- Mobilized advocates through educational resources, grassroots actions, and policy updates.
- Maintained momentum around one of the rare disease community's highest federal legislative priorities.

State Engagement Highlights




EMBOLDENING THE PATIENT COMMUNITY




Rare Disease Legislative Advocates (RDLA) is a program of the EveryLife Foundation for Rare Diseases designed to support the advocacy efforts of all rare disease patients and organizations.



In 2025, the 14th annual Rare Disease Week on Capitol Hill included advocates from 49 states, Washington, D.C., and Puerto Rico.



Rare Across America 2025 convened virtual Senate meetings and in-person House meetings at in-district offices.




In 2025, RDLA successfully organized Rare Disease State Advocacy Days in three locations, Virginia, Michigan, and New Jersey, to address the critical issues impacting rare disease patients.



Members of the rare disease community ages 10-18 years old met virtually with members of Congress to share their rare disease experiences. Prior to the meetings, online trainings on legislation and sharing their story were tailored for youth and teens.



A YEAR OF ADVOCACY



A community workspace created to foster cross-disease collaboration and advance or drive legislative advocacy in the heart of Washington, D.C.



Rare Advocacy Learning, launched in 2022, provides in-depth education and advocacy training, developing a pathway toward year-round advocacy engagement.



Pride in Rare held its first in-person meet-up at Rare Disease Week in 2025. An additional five meetings were held over the course of the year, providing an opportunity for the community to connect and network among others interested in the intersection of advocacy and identity.



Rare Artist provides a platform for artists to advocate through art.



YARRs are highly motivated rare disease community members between the ages of 16 and 30.



FINANCIAL SUPPORT TO THE COMMUNITY



The EveryLife Foundation’s Rare Giving program supports organizations that engage patients, caregivers, and others in the community in advocacy and public policy.

\$346,455 Total Awards

\$76,311 Tools & Resources Grants

\$73,725 Event Sponsorships

\$196,419 Rare Disease Week and State Advocacy Day Travel Reimbursements

"Receiving the Rare Giving Grant allowed us to offer robust and engaging programming for our Teen Group at our 2024 Family Conference in Aurora, CO! Our teens participated in a 'Telling Your Story' workshop and a 'Transition to Adulthood' workshop, had opportunities to mentor younger patients, and enjoyed a coffee shop outing where they could simply relax, chat, and build relationships with each other. Thank you to the EveryLife Foundation for making this a reality for our teens with HCU!"

— Liz Carter, Communications Manager, HCU Network America



Thanks to the support of Amgen, the EveryLife Foundation established the #RAREis Scholarship Fund to enrich the lives of adults living with rare diseases by providing support for their educational pursuits. In 2023, #RAREis provided its one millionth dollar.

\$540,000 In Scholarships Awarded in 2025

108 Community Scholarships provided
104 #RAREis
4 Segalman Family Scholarships for ALS

87 Disease Communities Represented

35 States Represented


39 #RAREis Scholarship Recipients Participated in a Scholarship Mentorship Pilot Program



The EveryLife Foundation was pleased to partner with Ultragenyx to bring patients and their families together for Rare Family Day in California.

140 Patients and Families Sponsored

7 Rare Artists Attended with their families




"I was genuinely excited about how the #RAREis Scholarship would help meet my needs and ease financial stress, but being matched with such an amazing mentor was more meaningful than I ever could have expected. Since I'm going to school out of state and far from home, having someone who truly understands what it's like to live with a rare disease has been incredibly comforting. It's made this experience feel so personal and impactful in a completely different way."

— Kylie Lindsey, 2025 #RAREis Scholarship



"Rare Family Day was not only a great opportunity to be with the rare disease community, but it made me feel seen. For an entire weekend, the weight of everything I hold inside, the exhaustion, the pain, and the unanswered questions were not in the forefront. I did not feel invisible but seen."


— Theresa Alo, Rare Artist Awardee



- \$540,000 In Educational Scholarships*
- \$25,220 In Event Sponsorships*
- \$151,880 10 Grants for Tools, Resources & Program Support
- \$6,975 In Donations Made to Organizations*
- \$231,392 In Travel Reimbursements*
- \$5,000 Rare Artist Awards*

*Data from August 2025

FINANCIALS



THANK YOU TO OUR
OUR ALLIANCE
DEVELOPMENT PARTNERS

- \$300,000 and Over**
- Amgen
 - Sanofi
 - Ultragenyx Pharmaceutical Inc.
- \$100,000 - \$299,999**
- Acadia Pharmaceuticals Inc.
 - Alexion Pharmaceuticals
 - Argenx US, Inc.
 - CSL Behring
 - Genentech, Inc
 - GSK plc
 - Merck & Co., Inc.
 - Novartis
 - Pfizer Inc.
 - Silicon Valley Community Foundation
 - Takeda Pharmaceutical
 - Traverse Therapeutics, Inc
- \$50,000 - \$99,999**
- Alnylam Pharmaceuticals, Inc
 - Amicus Therapeutics, Inc.
 - Avidity Biosciences, Inc.
 - BioCryst Pharmaceuticals, Inc.
 - Biogen, Inc.
 - BioMarin Pharmaceutical Inc.
 - Blueprint Medicines
 - Chiesi USA, Inc.
 - Ionis Pharmaceuticals, Inc.
 - Ipsen
 - Johnson & Johnson Services, Inc.
 - Kyowa Kirin Co., Ltd.
 - Neurocrine Biosciences, Inc.
 - Otsuka America Pharmaceutical, Inc
 - PhRMA
 - Sarepta Therapeutics, Inc.
 - Sobi
- \$25,000 - \$49,999**
- Alkermes plc
 - Astellas Pharma Inc.
 - Biotechnology Innovation Organization (BIO)
 - Boehringer-Ingelheim International
 - BridgeBio Pharma, Inc.
 - Burroughs Wellcome Fund
 - Denali Therapeutics
 - Eli Lilly and Company
 - Harmony Biosciences
- Incyte Corporation
 - IQVIA Inc.
 - Mallinckrodt Pharmaceuticals
 - Mitsubishi Tanabe Pharma America
 - Moderna
 - NS Pharma
 - Pharming Group
 - PTC Therapeutics, Inc.
 - Recordati Rare Diseases
 - Regenxbio, Inc.
 - Rhythm Pharmaceuticals, Inc.
 - Servier Pharmaceuticals
 - Solenio Therapeutics
 - Spark Therapeutics, Inc.
 - Stoke Therapeutics
 - Sumitomo Pharma America, Inc.
 - UCB SA
- \$10,000 - \$24,999**
- AdvaMed
 - Agios Pharmaceuticals, Inc.
 - Ascendis Pharma
 - Azafaros B. V.
 - Beam Therapeutics
 - Catalyst Pharmaceuticals
 - Cytokinetics
 - Danaher Corporation
 - Edgewise Therapeutics
 - Elevance Health
 - Entrada Therapeutics
 - Faegre Drinker Biddle & Reath LLP
 - GeneDx
 - Gilead Sciences
 - Illumina, Inc.
 - Insmed
 - Jazz Pharmaceuticals, Inc.
 - LabCorp
 - Mahzi Therapeutics
 - National Pharmaceutical Council
 - Novo Nordisk Inc
 - Ono Pharmaceutical Co., Ltd.
 - Orchard Therapeutics
 - Parexel
 - Revvity, Inc.
 - Rocket Pharmaceuticals
 - Savara Inc.
 - Scholar Rock
 - Stealth BioTherapeutics Inc.
 - The Assistance Fund
 - Vertex Pharmaceuticals Incorporated

BOARD OF DIRECTORS

- Executive Committee**
- Amy Gaviglio, MS, CGC, Chair
Public Health Genetics and Genomics Consultant, Connetics Consulting
 - James Valentine, JD, MHS, Vice Chair
Director, Hyman, Phelps & McNamara, P.C.
 - Jennifer Bernstein, Secretary
Principal, Monument Advocacy
 - Stephen Graft, Pharma D, Governance Chair, Treasurer
- Board Members**
- Ritu Baral
Managing Director, Health Care – Biotechnology, TD Cowen
 - Merrill Freidman
Regional Vice President, Inclusive Policy & Advocacy, Elevance Health
 - Eric Gascho
Vice President, CRD Associates
 - Michael Pearlmuter
Chief Executive Officer, The EveryLife Foundation
 - Sarah-Lloyd Stevenson
Senior Manager, Public Policy, Amazon
 - Shandra Trantham, PhD
Young Adult Rare Disease Advocate





"Rare Disease Week gave me the clarity to recognize my purpose and inspired me to pursue advocacy through storytelling. Thank you for helping me see a clear path forward."




Ellie Acuna
Mom of Rare Artist Awardee, Solana

"Rare Artist opened my eyes to a world I didn't know existed. At Rare Disease Week on Capitol Hill, I met another cane user who taught me how to use a blind cane and showed me I wasn't alone. Rare Artist also helped me earn an artist residency where I am creating tactile art for the low vision and blind community. Now I am on my way to doing the things I have dreamt of."



Lena Regina Smith
Rare Artist Awardee

"At times, having a rare disease can feel extremely lonely, but the YARR Leadership Academy really helped me remind myself that there are other people out there overcoming some of the same hardships I am."



Sarah Grace Cattell
2025 YARR Leadership Academy Graduate



501(c)(3) non-profit organization (Tax ID 26-4614274)

1012 14th St, NW, Suite 500, Washington, D.C. 20005
(202) 697-RARE (7273) info@everylifefoundation.org

everylifefoundation.org

